Soleus Capital Management’s Travere Therapeutics TVTX Stock Holding History

Soleus Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.2M	Buy	+546,000	New	+$16.3M	0.66%	40
2023 Q3	–	Sell	-21,600	Closed	-$332K	–	113
2023 Q2	$332K	Sell	21,600 -213,000	-91%	-$3.87M	0.04%	99
2023 Q1	$5.28M	Buy	+234,600	New	+$4.99M	0.55%	49
2021 Q4	–	Sell	-210,815	Closed	-$5.11M	–	87
2021 Q3	$5.11M	Buy	+210,815	New	+$3.87M	0.8%	37

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Soleus Capital Management's TVTX Position: Q1 2026 in Review

Soleus Capital Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 546,000 shares worth $16.2M. The stake represents 0.66% of the portfolio and ranks #40 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in TVTX as recently as Q2 2023.

Soleus Capital Management first reported a position in TVTX in Q3 2021 and has held it in 4 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Soleus Capital Management held 546,000 shares of Travere Therapeutics worth $16.2M as of Q1 2026.
Travere Therapeutics was a new Soleus Capital Management position in Q1 2026.
Travere Therapeutics made up 0.66% of Soleus Capital Management's portfolio in Q1 2026, its #40 holding.
Soleus Capital Management first reported a position in Travere Therapeutics in Q3 2021 and has held it in 4 quarters since.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.